RE:RE:RE:Ignore the haters
DavidRosenberg wrote: Mil_Man54 wrote: FSD has nothing of value....just PR BS....they won't have enough funds to finish even one of the trials and there is no hope of an institutional investor or a buy out by big pharma....FSD has a very poor reputation and is toxic to investors...and don't forget Roseburg...they tried to recruit volunteers for their trials of the same compound before with ONE applicant.
It's funny how you say that hopes and dreams are out of the shortseller handbook when all you ever say is "hopefully" and "time will tell"...you've still got nothing pumper....after 4 years all you do is continue to spread lies and misinformation....you really have no idea what your reputaion is in the investor and business community...let's just say it isn't good....not good at all.
They have nothing of value ? Sorry but I disagree
3 biotech assets , an exceptional biotech team with Julia levy award receipiant , although I agree 2022 was terrible year for most stocks they have the fundamentals in play , recruitment has started for fsd pea phase 2 , lucid MS if it gets FDA approval for IND phase 1 then I expect recruitment to start for that too we don't yet if FDA will approve the trial waiting news update for that
they have potent biotech team
the gears are now in play the seeds have been planted after the hurricane we wait to bear fruit
management doesn't need to please us I want them working hard to deliver results stock price is what all investors care about at the end of the day
2018 until now was been tough cookie to swallow
Covid 19 trials under previous ceo raza bokhari only yielded 1 patient and is laughable
this Management wants the same result as all shareholders to create meaningful biotech to improve the world as sick patients are our neighbors , friends and family and could affect anyone so this humanitarian mission to create new therapeutics that are not immunomodulatory like 100% of the MS drugs currently on market work by influencing the immune system by up regulating or down regulating certain immune system processes that's why FSD pharma lead candidate is unique and exciting because its mechanism of action doesn't rely on immune system to restore, paralyzed, limb, function, recovery.
if they can prove this works in human trials, this will be very good for shareholders. I pray this is the year things turn around, but only time will tell. Good luck guys.